LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

LLY

949.03

+1.48%↑

NVO

142.18

+1.62%↑

UNH

511.99

+1.33%↑

JNJ

149.82

+0.04%↑

MRK

127.38

-1.16%↓

Search

BioCryst Pharmaceuticals Inc

Suletud

Sektor Tervishoid

7.16 1.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

7.14

Max

7.18

Põhinäitajad

By Trading Economics

Sissetulek

-36M

Müük

6.7M

93M

Aktsiakasum

-0.28

Kasumimarginaal

-41.674

Töötajad

536

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+115.1 upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

1. aug 2024

Turustatistika

By TradingEconomics

Turukapital

41M

990M

Eelmine avamishind

5.74

Eelmine sulgemishind

7.16

Uudiste sentiment

By Acuity

50%

50%

117 / 369 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

BioCryst Pharmaceuticals Inc Graafik

Seotud uudised

12. juuli 2024, 22:05 UTC

Omandamised, ülevõtmised, äriostud

Pactiv Evergreen Sells Paper Mill, Extrusion Facility to Suzano for $110 Million

12. juuli 2024, 20:18 UTC

Omandamised, ülevõtmised, äriostud

Lundin Mining Approaches BHP to Buy Copper Miner Filo, Bloomberg Reports

12. juuli 2024, 19:57 UTC

Suurimad hinnamuutused turgudel

Instil Bio Shares Surge Following Rental Agreement with AstraZeneca

12. juuli 2024, 18:13 UTC

Peamised uudised

Elon Musk's X Found in Breach of EU Digital-Content Law -- 2nd Update

12. juuli 2024, 23:29 UTC

Omandamised, ülevõtmised, äriostud

BP Says Oil Demand Is Falling, While OPEC Says It's Rising. What Gives? -- Barrons.com

12. juuli 2024, 21:50 UTC

Omandamised, ülevõtmised, äriostud

Pactiv Evergreen Sells Paper Mill, Extrusion Facility to Suzano for $110M

12. juuli 2024, 21:03 UTC

Peamised uudised
Omandamised, ülevõtmised, äriostud

The Score: Microsoft, Delta Air Lines, Wells Fargo and More Stocks That Defined the Week -- WSJ

12. juuli 2024, 20:50 UTC

Market Talk

Health Care Roundup: Market Talk

12. juuli 2024, 20:41 UTC

Peamised uudised

Dow Rises With Investors Putting Rate Cut in Sight -- WSJ

12. juuli 2024, 20:38 UTC

Omandamised, ülevõtmised, äriostud

Ansys: Synopsys Submits Notification of Transaction to China Regulator for Purchase of Ansys

12. juuli 2024, 20:26 UTC

Peamised uudised
Tulu

Big Banks Continue to Feel Pressure From Higher Rates -- 3rd Update

12. juuli 2024, 20:19 UTC

Tulu

These Stocks Moved the Most Today: Tesla, Wells Fargo, JPMorgan, BNY, Nvidia, and More -- Barrons.com

12. juuli 2024, 19:26 UTC

Tulu

Correction to Big Banks Continue to Feel Pressure From Higher Rates Article -- WSJ

12. juuli 2024, 19:07 UTC

Market Talk

U.S. Natural Gas Futures Snap 3-Day Losing Streak -- Market Talk

12. juuli 2024, 17:52 UTC

Peamised uudised
Tulu

Big Banks Continue to Feel Pressure From Higher Rates -- 3rd Update

12. juuli 2024, 17:34 UTC

Market Talk

Gold Takes Pause After Surge -- Market Talk

12. juuli 2024, 17:31 UTC

Market Talk

U.S. Oil Rig Count Down By 1 to 478 -- Market Talk

12. juuli 2024, 17:22 UTC

Market Talk

Private-Capital Investing For Solar Developers Dropped in 1H -- Market Talk

12. juuli 2024, 17:01 UTC

Peamised uudised

AT&T Says Hacker Stole Cell, Text Data on Nearly All Its Wireless Customers -- 2nd Update

12. juuli 2024, 16:45 UTC

Market Talk

Nike's Corporate Plan Step in Right Direction, but Challenges Mount -- Market Talk

12. juuli 2024, 16:44 UTC

Market Talk

Estée Lauder CFO Change Needs to Offer Fresh Perspective -- Market Talk

12. juuli 2024, 16:20 UTC

Market Talk

Health Care Roundup: Market Talk

12. juuli 2024, 16:08 UTC

Market Talk

Gold Futures Pare Some Gains But Hold Above $2,400 on Soft Inflation Data -- Market Talk

12. juuli 2024, 16:02 UTC

Peamised uudised

Big Banks Continue to Feel Pressure From Higher Rates -- 2nd Update

12. juuli 2024, 15:45 UTC

Market Talk

KC Fed Seeing Green Shoots in Energy Activity -- Market Talk

12. juuli 2024, 15:43 UTC

Market Talk

Bank of Canada Likely Thrilled With Housing-Market Data -- Market Talk

12. juuli 2024, 15:39 UTC

Market Talk

Canada Home-Sales Activity 'Subdued' Despite Rise in June -- Market Talk

12. juuli 2024, 15:36 UTC

Peamised uudised

Berkshire Hathaway Stock Hits Record. Warren Buffett's Stake at $133 Billion. -- Barrons.com

12. juuli 2024, 15:32 UTC

Peamised uudised

AT&T Says Hacker Stole Cell, Text Data on Nearly All Its Wireless Customers -- Update

12. juuli 2024, 15:32 UTC

Market Talk

Boeing Profits Lost In Space -- Market Talk

Võrdlus sarnastega

Hinnamuutus

BioCryst Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

115.1% tõus

12 kuu keskmine prognoos

Keskmine 15.38 USD  115.1%

Kõrge 30 USD

Madal 6 USD

Põhineb 8 Wall Streeti analüütiku instrumendi BioCryst Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

6.1 / 7.65Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Strong Bullish Evidence

Pikk perspektiiv

Strong Bearish Evidence

Sentiment

By Acuity

117 / 369 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc. discovers oral and small-molecule medicines that treat rare diseases in which unmet medical needs exist and an enzyme plays the key role in the biological pathway of the disease. ORLADEYO (berotralstat) is an oral, once-daily therapy that is approved in the United States, the European Union, Japan, and the United Kingdom for the prevention of hereditary angioedema attacks in adults and pediatric patients 12 years and older. The Company has several ongoing development programs, including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases; BCX9250, an activin receptor-like kinase-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, an antiviral drug for Marburg virus disease and Yellow Fever. RAPIVAB (peramivir injection) is a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the United States, Canada, Australia, Japan, Taiwan and Korea.